Nataliya V. Tupikina
Nataliya V. Tupikina has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Gevorg R. Kasyan
Urology Department, Moscow State University of Medicine and Dentistry, Moscow, Russian Federation
5 shared publications - Dmitrii Yu. Pushkar
Russian University of Medicine, Ministry of Health of Russia; S. P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow Healthcare Department
4 shared publications M.Y. Gvozdev
3 shared publicationsA.V. Glotov
2 shared publicationsB.N. Godunov
1 shared publicationDmitry Y. Pushkar
1 shared publication
Latest Publications
- Open Access
- 1 December 2019
- Published by Elsevier in Urology Video Journal
- Vol. 4
A new surgical approach for managing iatrogenic urinary obstruction after midurethral sling surgery
- 1 December 2019
- Published by Elsevier in Urology Video Journal
- Vol. 4
Open AccessA new surgical approach for managing iatrogenic urinary obstruction after midurethral sling surgery
- Open Access
- 30 March 2017
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 13 (1) , 67-73-73
Prognostic role of Ki-67 expression in determination of risk of non-muscle invasive bladder cancer recurrence
Introduction. To increase accuracy of disease prognosis in patients with bladder cancer we propose determination of expression level of several tumor markers. Objective is evaluation of prognostic significance of Ki-67 expression level in risk of non-muscle invasive bladder cancer recurrence.Materials and methods. To perform immunohistochemistry analysis of Ki-67 we used surgery material of 83 patients who underwent primary transurethral bladder resection due to non-muscle invasive cancer. We performed an analysis of correlation between Ki-67 expression level in malignant tissue removed by transurethral resection and characteristics of tumor development. We evaluated the role of Ki-67 in stratification of recurrence risk by comparing the level of Ki-67 antigen expression in patients with recurrent non-muscle invasive bladder cancer and in relapse-free patients. We present evaluation of sensitivity, specificity, and prognostic value of quantitative determination of Ki-67 expression level in relation to non-muscle invasive bladder cancer recurrence.Results. During the follow-up period, 41 cases of non-muscle invasive bladder tumor recurrence were observed. Quantitative value of the Ki-67 marker correlated with tumor differentiation grade G, malignancy grade, invasion into submucosal and muscle layers, presence of primary process, and tumor recurrence. In comparison with relapse-free patients, a significantly higher level of Ki-67 expression was observed in patients with cancer recurrence (р = 0.0035). We have determined a threshold quantitative value of Ki-67 (48 %) indicating disease recurrence. Presence of a threshold value of the Ki-67 marker showed moderate sensitivity level (less than 71 %) with relatively low specificity level (57 %). However prognostic level wasn’t high (between 63 and 65 %).Conclusion. In patients with recurrent non-muscle invasive bladder cancer an elevated level of Ki-67 expression was observed in comparison with relapse-free patients (test sensitivity was 70.7 %). Obviously, determination of molecular biomarkers, Ki-67 in particular, can potentially help distinguish highly malignant tumors with high progression and recurrence risk, which can significantly improve treatment results for these patients. However, this problem requires further research.
- 30 March 2017
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 13 (1) , 67-73-73
Open AccessPrognostic role of Ki-67 expression in determination of risk of non-muscle invasive bladder cancer recurrence
Introduction. To increase accuracy of disease prognosis in patients with bladder cancer we propose determination of expression level of several tumor markers. Objective is evaluation of prognostic significance of Ki-67 expression level in risk of non-muscle invasive bladder cancer recurrence.Materials and methods. To perform immunohistochemistry analysis of Ki-67 we used surgery material of 83 patients who underwent primary transurethral bladder resection due to non-muscle invasive cancer. We performed an analysis of correlation between Ki-67 expression level in malignant tissue removed by transurethral resection and characteristics of tumor development. We evaluated the role of Ki-67 in stratification of recurrence risk by comparing the level of Ki-67 antigen expression in patients with recurrent non-muscle invasive bladder cancer and in relapse-free patients. We present evaluation of sensitivity, specificity, and prognostic value of quantitative determination of Ki-67 expression level in relation to non-muscle invasive bladder cancer recurrence.Results. During the follow-up period, 41 cases of non-muscle invasive bladder tumor recurrence were observed. Quantitative value of the Ki-67 marker correlated with tumor differentiation grade G, malignancy grade, invasion into submucosal and muscle layers, presence of primary process, and tumor recurrence. In comparison with relapse-free patients, a significantly higher level of Ki-67 expression was observed in patients with cancer recurrence (р = 0.0035). We have determined a threshold quantitative value of Ki-67 (48 %) indicating disease recurrence. Presence of a threshold value of the Ki-67 marker showed moderate sensitivity level (less than 71 %) with relatively low specificity level (57 %). However prognostic level wasn’t high (between 63 and 65 %).Conclusion. In patients with recurrent non-muscle invasive bladder cancer an elevated level of Ki-67 expression was observed in comparison with relapse-free patients (test sensitivity was 70.7 %). Obviously, determination of molecular biomarkers, Ki-67 in particular, can potentially help distinguish highly malignant tumors with high progression and recurrence risk, which can significantly improve treatment results for these patients. However, this problem requires further research.
- 1 April 2015
- Published by Elsevier in European Urology Supplements
- Vol. 14 (2) , e985-e985a
985 Novel method for evaluation of pelvic floor mobility in women with genital prolapse and stress urinary incontinence
- 1 April 2015
- Published by Elsevier in European Urology Supplements
- Vol. 14 (2) , e985-e985a
985 Novel method for evaluation of pelvic floor mobility in women with genital prolapse and stress urinary incontinence
- 1 April 2014
- Published by Elsevier in European Urology Supplements
- Vol. 13 (1) , e377
377 Follow up for urinary continence after pelvic organ prolapse repair
- 1 April 2014
- Published by Elsevier in European Urology Supplements
- Vol. 13 (1) , e377
377 Follow up for urinary continence after pelvic organ prolapse repair
- 1 April 2014
- Published by Elsevier in European Urology Supplements
- Vol. 13 (1) , e376
376 The prognostic value of the cough test in patients suffering from pelvic organ prolapse
- 1 April 2014
- Published by Elsevier in European Urology Supplements
- Vol. 13 (1) , e376
376 The prognostic value of the cough test in patients suffering from pelvic organ prolapse
- Open Access
- 1 January 2014
- Published by Polskie Towarzystwo Urologiczne in Central European Journal of Urology
- Vol. 67 (2) , 202-7
Use of Martius flap in the complex female urethral surgery
Objectives were to evaluate safety and patient reported perception of the Martius fibroadipose flap for complex female urethra reconstruction. Patients operated with a Martius flap were contacted again via telephone to rate their self-perception on cosmetic appearance, pain or numbness of the flap harvest site. 37 women (mean age of 46.8 yrs.) were operated with Martius flaps. Complications were limited to bleeding from the flap bed in 19% (7/37); hematomas - 5.4% (2/37); and lymphorrhea from the labial incision in 13.5% (5/37) and labial wound infection in 5.4% of cases (2/37). For self-perception 65% of patients (24/37) were phone interviewed (mean follow up - 54.2 months). Only 17% of women (4/24) complained to cosmetic problems. Two patients (8%) complained to a periodical mild pain. And 12.5% (3/24) of the women had decreased sensation or numbness at the labia. Martius flap is safe and it is not causing significant complications during female urethral reconstruction. However, an informed consent for decreased sensation and numbness at the flap harvesting area should be obtained.
- 1 January 2014
- Published by Polskie Towarzystwo Urologiczne in Central European Journal of Urology
- Vol. 67 (2) , 202-7
Open AccessUse of Martius flap in the complex female urethral surgery
Objectives were to evaluate safety and patient reported perception of the Martius fibroadipose flap for complex female urethra reconstruction. Patients operated with a Martius flap were contacted again via telephone to rate their self-perception on cosmetic appearance, pain or numbness of the flap harvest site. 37 women (mean age of 46.8 yrs.) were operated with Martius flaps. Complications were limited to bleeding from the flap bed in 19% (7/37); hematomas - 5.4% (2/37); and lymphorrhea from the labial incision in 13.5% (5/37) and labial wound infection in 5.4% of cases (2/37). For self-perception 65% of patients (24/37) were phone interviewed (mean follow up - 54.2 months). Only 17% of women (4/24) complained to cosmetic problems. Two patients (8%) complained to a periodical mild pain. And 12.5% (3/24) of the women had decreased sensation or numbness at the labia. Martius flap is safe and it is not causing significant complications during female urethral reconstruction. However, an informed consent for decreased sensation and numbness at the flap harvesting area should be obtained.